What is SYRS stock price today?

SYRS (Syros Pharmaceuticals Inc) stock is trading at $0.00 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SYRS stock going up or down today?

SYRS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SYRS stock now?

The decision to buy SYRS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SYRS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SYRS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SYRS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if SYRS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is SYRS's P/E ratio?

P/E ratio data for SYRS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is SYRS's market cap?

SYRS (Syros Pharmaceuticals Inc) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is SYRS's price to book ratio?

SYRS trades at a price-to-book (P/B) ratio of 10.65, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does SYRS pay dividends?

SYRS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is SYRS's dividend yield?

SYRS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is SYRS stock a good long-term investment?

SYRS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is SYRS's revenue growth rate?

SYRS has shown revenue growth of -0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for SYRS are available on our dashboard with complete income statement analysis.

What are the risks of investing in SYRS?

Key risks for SYRS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does SYRS compare to its competitors?

Compare SYRS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize SYRS's performance and positioning.

What is SYRS's stock price target for 2026?

Our AI model provides price targets for SYRS based on fundamental analysis: Bull case $0.00 (+30%), Base case $0.00 (+15%), Bear case $0.00 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about SYRS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for SYRS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is SYRS's next earnings report?

SYRS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

SYRS - Syros Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$0.00

+$0.00 (+0.00%)

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Key Statistics

Market Cap

$0.01M

P/B Ratio

10.65

EPS

$-1.75

Revenue Growth

-0.0%

Employees

How SYRS Compares to Peers

SYRS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
SYRS(This stock)	$5.37K	N/A	-0%	0.0%	-
AMGNAmgen Inc	$191.53B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Syros Pharmaceuticals Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.syros.com
Sector: Health Care
Industry: Biotechnology

SYRS - Syros Pharmaceuticals Inc

About Syros Pharmaceuticals Inc

SYRS Key Statistics

How SYRS Compares to Peers

Syros Pharmaceuticals Inc Company Information

SYRS Lician Score

SYRS Financial Snowflake

Upcoming Events for SYRS